BioCentury | Dec 17, 2007
Company News

Protein'eXpert, Stallergenes deal

The partners began a double-blind, active- and placebo-controlled, Scandinavian Phase III trial designed to assess non-inferiority of 10 or 20 mg daily doses of oral balaglitizone versus 45 mg daily of Actos piaglitizone over 6...
BioCentury | May 5, 2003
Company News

Eurogentec, Protein'eXpert sales and marketing update

...Eurogentec will distribute Protein'eXpert's ProX'test protein expression and scale-up technology. Eurogentec S.A ., Liege, Belgium Protein'eXpert S.A....
Items per page:
1 - 2 of 2
BioCentury | Dec 17, 2007
Company News

Protein'eXpert, Stallergenes deal

The partners began a double-blind, active- and placebo-controlled, Scandinavian Phase III trial designed to assess non-inferiority of 10 or 20 mg daily doses of oral balaglitizone versus 45 mg daily of Actos piaglitizone over 6...
BioCentury | May 5, 2003
Company News

Eurogentec, Protein'eXpert sales and marketing update

...Eurogentec will distribute Protein'eXpert's ProX'test protein expression and scale-up technology. Eurogentec S.A ., Liege, Belgium Protein'eXpert S.A....
Items per page:
1 - 2 of 2